Comparing QuantiFERON-TB Gold Plus with QuantiFERON-TB Gold in-tube for diagnosis of latent tuberculosis infection among highly TB exposed gold miners in South Africa.

Autor:	Ntshiqa T; Implementation Research Division, The Aurum Institute, Johannesburg, Gauteng, 2193, South Africa., Chihota V; Implementation Research Division, The Aurum Institute, Johannesburg, Gauteng, 2193, South Africa.; School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, 2193, South Africa., Mansukhani R; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, WC1E 7HT, UK., Nhlangulela L; Implementation Research Division, The Aurum Institute, Johannesburg, Gauteng, 2193, South Africa., Velen K; Implementation Research Division, The Aurum Institute, Johannesburg, Gauteng, 2193, South Africa., Charalambous S; Implementation Research Division, The Aurum Institute, Johannesburg, Gauteng, 2193, South Africa.; School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, 2193, South Africa., Maenetje P; Implementation Research Division, The Aurum Institute, Johannesburg, Gauteng, 2193, South Africa., Hawn TR; Department of Medicine, University of Washington, Seattle, Seattle, New York, 98195, USA., Wallis R; Implementation Research Division, The Aurum Institute, Johannesburg, Gauteng, 2193, South Africa., Grant AD; School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, 2193, South Africa.; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, WC1E 7HT, UK.; Africa Health Research Institute, Laboratory Medicine & Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, KwaZulu-Natal, 4041, South Africa., Fielding K; School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, 2193, South Africa.; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, WC1E 7HT, UK., Churchyard G; Implementation Research Division, The Aurum Institute, Johannesburg, Gauteng, 2193, South Africa.; School of Public Health, University of the Witwatersrand, Johannesburg, Gauteng, 2193, South Africa.
Jazyk:	angličtina
Zdroj:	Gates open research [Gates Open Res] 2022 Aug 18; Vol. 5, pp. 66. Date of Electronic Publication: 2022 Aug 18 (Print Publication: 2021).
DOI:	10.12688/gatesopenres.13191.3
Abstrakt:	Background: QuantiFERON-TB-Gold-in-tube (QFT-GIT) is an interferon-gamma release assay (IGRA) used to diagnose latent tuberculosis infection. Limited data exists on performance of QuantiFERON-TB Gold-Plus (QFT-Plus), a next generation of IGRA that includes an additional antigen tube 2 (TB2) while excluding TB7.7 from antigen tube 1 (TB1), to measure TB specific CD4+ and CD8+ T lymphocytes responses. We compared agreement between QFT-Plus and QFT-GIT among highly TB exposed goldminers in South Africa. Methods: We enrolled HIV-negative goldminers in South Africa, aged ≥33 years with no prior history of TB disease or evidence of silicosis. Blood samples were collected for QFT-GIT and QFT-Plus. QFT-GIT was considered positive if TB1 tested positive; while QFT-Plus was positive if both or either TB1 or TB2 tested positive, as per manufacturer's recommendations. We compared the agreement between QFT-Plus and QFT-GIT using Cohen's Kappa. To assess the specific contribution of CD8+ T-cells, we used TB2-TB1 differential values as an indirect estimate. A cut-off value was set at 0.6. Logistic regression was used to identify factors associated with having TB2-TB1>0.6 difference on QFT-Plus. Results: Of 349 enrolled participants, 304 had QFT-Plus and QFT-GIT results: 205 (68%) were positive on both assays; 83 (27%) were negative on both assays while 16 (5%) had discordant results. Overall, there was 94.7% (288/304) agreement between QFT-Plus and QFT-GIT (Kappa = 0.87). 214 had positive QFT-Plus result, of whom 202 [94.4%, median interquartile range (IQR): 3.06 (1.31, 7.00)] were positive on TB1 and 205 [95.8%, median (IQR): 3.25 (1.53, 8.02)] were positive on TB2. A TB2-TB1>0.6 difference was observed in 16.4% (35/214), with some evidence of a difference by BMI; 14.9% (7/47), 9.8% (9/92) and 25.3% (19/75) for BMI of 18.5-24.9, 18.5-25 and >30 kg/m 2, respectively (P=0.03). Conclusion: In a population of HIV-negative goldminers, QFT-Plus showed high agreement with QFT-GIT, suggesting similar performance. Competing Interests: No competing interests were disclosed. (Copyright: © 2022 Ntshiqa T et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu